9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Estimated reading time: < 1 min

Condition: Advanced Malignancies

Estimated Enrollment: 285

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: 1. Phase 1: Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs),  Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,  Phase 1: ORR based on RECIST v1.1 and modified RECIST v1.1 (mRECIST v1.1), Phase 1 & Phase 2: Duration of response based on RECIST v1.1 and mRECIST v1.1

Interventions: INCAGN01876, Nivolumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: January 2020

Completion Date: March 2020

Last  Posted Date: June 21, 2019

Location: The Angeles Clinic and Research Institute, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03126110

Was this article helpful?
Dislike 0